Skip to main content
main-content

Diabetes complications and comorbidities

Highlights

04-15-2019 | Nephropathy | Highlight | News

Canagliflozin may offer renal protection in people with type 2 diabetes and CKD

Findings from the CREDENCE trial indicate that the SGLT2 inhibitor canagliflozin reduces the risk for renal failure and cardiovascular disease among individuals with type 2 diabetes and albuminuric chronic kidney disease.

02-19-2019 | Ketoacidosis | Highlight | News

Data highlight opportunities to diagnose type 1 diabetes before DKA onset

Children with type 1 diabetes are more likely than their non-diabetic peers to seek primary care for a number of specific conditions in the year before their diagnosis, which could aid detection before the onset of diabetic ketoacidosis, say researchers.

02-12-2019 | SGLT2 inhibitors | Highlight | News

Recommendations issued for managing SGLT inhibitor-associated DKA risk in type 1 diabetes

Experts have developed consensus recommendations for minimizing diabetic ketoacidosis risk in patients with type 1 diabetes treated with SGLT inhibitors.

01-17-2019 | Glucokinase activators | Highlight | News

Hepatic glucokinase activation may improve glycemic control in type 2 diabetes

The hepatoselective glucokinase activator TTP399 reduces glycated hemoglobin levels without increasing the risk for hypoglycemia among patients with type 2 diabetes, suggest findings from the phase IIb AGATA trial.

01-02-2019 | Canagliflozin | medwireNews | News

No fracture risk found with canagliflozin in real-world data

Research based on insurance claims data indicates that new users of the sodium-glucose cotransporter-2 inhibitor canagliflozin are no more likely to experience a fracture than new users of glucagon-like peptide-1 receptor agonists.

12-14-2018 | Risk factors | Feature | Article

Sleep duration: Waking up to a major metabolic risk factor

The effect of sleep duration on glucose regulation and cardiometabolic risk is becoming an increasingly high-profile issue. medwireNews takes a look at the latest evidence, which shows the gravity of the problem but also offers some solutions.

11-10-2018 | Dapagliflozin | Highlight | News

DECLARE-TIMI 58 supports CV benefits of SGLT2 inhibitor class

The results of the DECLARE-TIMI 58 trial show a broadly positive effect of dapagliflozin on cardiovascular outcomes, especially heart failure, in patients with type 2 diabetes.

10-22-2018 | Mental health | Highlight | News

Insulin manipulation strongly linked to psychiatric comorbidity

Insulin manipulation, the practice of deliberately under- or overdosing insulin, is strongly associated with psychiatric comorbidity in children and young adults with type 1 diabetes, Austrian research shows.

10-05-2018 | Hyperglycemia | EASD 2018 | News

ADA/EASD consensus report on managing hyperglycemia in type 2 diabetes published

The final version of the 2018 update to the consensus guidelines on managing hyperglycemia in people with type 2 diabetes is now published.

10-04-2018 | Empagliflozin | EASD 2018 | News

EASE: Add-on empagliflozin improves glycemic control in type 1 diabetes

The addition of empagliflozin to insulin therapy reduces glycated hemoglobin levels in patients with type 1 diabetes, indicate findings from the phase III EASE-2 and 3 trials.

09-24-2018 | Diabetic foot ulcers | medwireNews | News

LeucoPatch improves healing of difficult diabetic foot ulcers

Weekly application of an autologous immune cell, fibrin, and platelet patch significantly increases the rate of healing of hard-to-heal foot ulcers compared with standard care in people with diabetes, randomized trial data show.

09-18-2018 | Sexual dysfunction | View from the clinic | Article

Regaining sexual health in diabetes: Start with open communication

Advisory Board member Clipper Young recounts an experience of starting a patient with erectile dysfunction on the path to appropriate treatment for him and his diabetes.

09-05-2018 | Diagnosis | Case study | Article

Acute illness while on a SGLT2 inhibitor and ketogenic diet

Advisory Board member Theresa Smyth tackles an emergency case in a type 2 diabetes patient treated with empagliflozin. What went wrong and how should he be managed?

08-29-2018 | Blood glucose monitoring | Editorial | Article

The ambulatory glucose profile: What, why, and how?

Editorial Board member Lori Berard discusses how the ambulatory glucose profile is quietly revolutionizing the analysis of blood glucose and glycemic control for patients and practitioners.

08-26-2018 | Lorcaserin | Highlight | News

Neutral cardiovascular safety for lorcaserin in CAMELLIA-TIMI 61

The weight-loss medication lorcaserin neither increases nor reduces cardiovascular risk, report the CAMELLIA–TIMI 61 investigators.

08-18-2018 | Continuous glucose monitoring | Review | Article

Prevention and management of severe hypoglycemia and hypoglycemia unawareness: Incorporating sensor technology

Lucidi P et al. Curr Diab Rep 2018; 18: 83. doi: 10.1007/s11892-018-1065-6

08-15-2018 | SGLT2 inhibitors | Highlight | News

Research adds to SGLT2 inhibitor amputation risk debate

Researchers have found evidence to support an increased risk for amputation among patients with type 2 diabetes taking sodium-glucose cotransporter 2 inhibitors relative to some oral treatments.

08-15-2018 | Neuropathy | Editorial | Article

Are we using the right tests to diagnose diabetic neuropathy?

Uazman Alam and colleagues interrogate current evidence and real-world clinical scenarios to address whether enough is being done with the tools available to screen and diagnose diabetic neuropathy.

08-06-2018 | Metabolic surgery | Highlight | News

Real-world bariatric surgery data show microvascular protection

Obese patients with type 2 diabetes who undergo bariatric surgery achieve large reductions in their risk for microvascular complications, shows a real-world study.

07-18-2018 | Sulfonylureas | Highlight | News

Continuing metformin advisable for patients starting sulfonylurea treatment

Research shows that starting second-line sulfonylurea treatment is associated with an increased risk for cardiovascular and hypoglycemic events among patients with type 2 diabetes in clinical practice, although the risk is less if they continue using metformin rather than switching completely.

Image Credits